浩欧博股价涨5.3%，华富基金旗下1只基金重仓，持有3.2万股浮盈赚取27.2万元

Group 1 - The core viewpoint of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. has seen a stock price increase of 5.3%, reaching 169.00 CNY per share, with a total market capitalization of 10.728 billion CNY [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - Huafu Fund has a significant holding in Haobo Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 32,000 shares, representing 5.87% of the fund's net value [2] - The fund has achieved a year-to-date return of 64.07%, ranking 409 out of 8172 in its category, and a one-year return of 69.47%, ranking 1687 out of 7980 [2] - The fund manager, Liao Qingyang, has been in charge for 3 years and 313 days, with the best fund return during this period being 43.34% [2]